Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "FGFR3 Alterations in Phase III PROOF 302 Trial: Infigratinib (BGJ398) as Adjuvant Therapy in Patients With Invasive Urothelial Carcinoma"
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Petros Grivas
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Petros Grivas
Login to view comments.
Click here to Login